DreamCIS, Inc. (KOSDAQ:223250)

South Korea · Delayed Price · Currency is KRW

3,320.00

-135.00 (-3.91%)

At close: Jun 30, 2026

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Clinical Trial Human Resources Support Department	5.66B	1.09B	-	-	-
Clinical Trial Human Resources Support Department Growth	417.31%	-	-	-	-
Consolidation Adjustment	-3.80B	-2.78B	-1.72B	-576.65M	-
Medical Consulting	15.43B	15.05B	15.14B	7.25B	-
Medical Consulting Growth	2.50%	-0.60%	108.86%	-	-
Clinical Trial Management Agency	49.35B	45.28B	34.42B	32.20B	-
Clinical Trial Management Agency Growth	8.97%	31.55%	6.90%	-	-
Total	66.63B	58.65B	47.84B	38.87B	-
Total Growth	13.60%	22.59%	23.08%	-	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
South Korea	62.13B	52.51B	43.36B	34.24B	23.24B
South Korea Growth	18.32%	21.11%	26.62%	47.34%	13.38%
Overseas	4.50B	6.14B	4.49B	4.63B	2.91B
Overseas Growth	-26.74%	36.92%	-3.11%	58.96%	-2.63%
Total	66.63B	58.65B	47.84B	38.87B	26.15B
Total Growth	13.60%	22.59%	23.08%	48.64%	11.34%